Pasireotide is a novel, multireceptor-targeted somatostatin analogue with high binding affinity for sst1,2,3 and sst5 that has been approved for the treatment of Cushing’s disease [80–82] and acromegaly [13, 14, 83, 84]. This evidence concerns the gene SSTR5 and acromegaly.